MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_DNA, RNA, RNAi, siRNA & mRNA
Avidity Biosciences, Inc. (NASDAQ: RNA)
Organization & Developments: Avidity Biosciences
Parents
Avidity Biosciences, Inc. (NASDAQ: RNA)
Children
*Avidity Biosciences is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases.
2022: Avidity Biosciences Stock Soars On New RNA Data
2022: Highly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study
2023: A First Look At Avidity Biosciences_ seekingalpha.com
2024 Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch
2024: Analysts dig into details of Avidity's DMD win, revealing nuances in strong data
2024: Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases
2024: Avidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Data
2024: Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders
Jumps
Finance & Acquisition: Avidity Biosciences
Key People: Avidity Biosciences